Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Evommune, Inc.NYSE: EVMN
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q1 FY2026 other non-current liabilities was $0, compared with $6K a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 16K | -93.5% |
| FY2023 | 2023-12-31 | 245K | — |
Other Non-current Liabilities vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 other non-current liabilities of $0 is the 8th highest of the 10 companies compared; the peer median is $1.34M.
- Its year-over-year change of -100.0% is the lowest of 8, against a peer median of +4.1%.
- Other non-current liabilities amounts to 0.0% of total assets for EVMN, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $92.09M | +33024.8% | -54.6% | 7.8% | |
FTREFortrea Holdings Inc. | Jun 2026 | $38.5M | +4.1% | +21.9% | 1.4% |
| Jun 2026 | $19.6M | +6.1% | -51.1% | 0.9% | |
| Mar 2026 | $9.8M | -88.0% | -42.4% | 7.5% | |
| Mar 2026 | $1.34M | +4.1% | -1.1% | 1.0% | |
| Mar 2026 | $481K | +24.9% | -54.4% | 0.2% | |
| Mar 2026 | $55K | -68.9% | -47.5% | 0.0% | |
EVMNEvommune, Inc. | Mar 2026 | $0 | -100.0% | — | 0.0% |
CLYMClimb Bio, Inc. | Mar 2026 | $0 | — | — | 0.0% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding EVMN) | $1.34M | +4.1% | -47.5% | 0.9% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.